tbuckley/cabot-search huggingface dataset:
New technologies attract patients with prostate cancer to treatment centres, study finds
Authors: Susan Mayor
Journal: BMJ (2017)

The availability of new technologies such as robotic systems is attracting patients to cancer surgery centres rather than evidence of quality of care, a study of patients undergoing prostate cancer surgery in England has found.1

Several countries, including the UK, have introduced policies that allow patients to choose a specific healthcare provider, with the aim of improving quality of care. Previous research has shown that patients are willing to travel to centres other than their nearest hospital for cancer surgery, but information on how they make this choice has been limited. …
Synthesis of Metal Nanoparticles in Metal‐Phenolic Networks: Catalytic and Antimicrobial Applications of Coated Textiles
Authors: Gyeongwon Yun, Shuaijun Pan, Ting‐Yi Wang, Junling Guo, Joseph J. Richardson, Frank Caruso
Journal: Advanced Healthcare Materials (2017)

The synthesis of metal nanoparticle (NP)-coated textiles (nanotextiles) is achieved by a dipping process in water without toxic chemicals or complicated synthetic procedures. By taking advantage of the unique nature of tannic acid, metal-phenolic network-coated textiles serve as reducing and stabilizing sites for the generation of metal nanoparticles of controllable size. The textiles can be decorated with various metal nanoparticles, including palladium, silver, or gold, and exhibit properties derived from the presence of the metal nanoparticles, for example, catalytic activity in water (>96% over five cycles using palladium nanoparticles) and antibacterial activity against Gram-negative bacteria (inhibition of Escherichia coli using silver nanoparticles) that outperforms a commercial bandage. The reported strategy offers opportunities for the development of hybrid nanomaterials that may have application in fields outside of catalysis and antimicrobials, such as sensing and smart clothing.
Kawasaki disease
Authors: N. Curtis
Journal: BMJ (1997)

Dr Tomisaku Kawasaki described the disease that bears his name nearly 30 years ago.1 Kawasaki disease is now the commonest cause of acquired heart disease in children in developed countries. Its cause remains unknown, and it presents doctors with many difficulties in diagnosis and management. Kawasaki disease is a systemic febrile vasculitis predominantly affecting children aged under 5 years. The incidence in Britain is 3.4 per 100 000 children aged under 5 years2—about a third of the incidence reported in the United States and a 30th of that in Japan.3 The most important complication, coronary arteritis leading to formation of aneurysms, occurs in 20-30% of untreated patients.3 Thrombosis within an aneurysm, myocardial infarction, and dysrhythmias may occur in the acute phase of the illness. The case fatality rate in Britain in 1990 was 3.7%,2 which compares unfavourably with the United States and Japan, where in some centres it is as low as 0.1%.2 Patients also suffer long term morbidity as a result of scarring of coronary arteries, intimal thickening, and accelerated atherosclerosis.3 #### Diagnostic criteria for Kawasaki disease Presence of at least five of six conditions: Reddened, dry, or cracked lips Strawberry tongue … RETURN TO TEXT
Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME)
Authors: A. Bex, P. Mulders, M.A.S. Jewett, J. Wagstaff, R. van Velthoven, P.M. Laguna Pes, L. Wood, H.H.E. van Melick, P. Soetekouw, J.B. Lattouf, T. Powles, E. Boleti, I-J. de Jong, S. Rottey, B. Tombal, S. Marreaud, L. Collette, S. Collette, C.U. Blank, J.B. Haanen
Journal: Annals of Oncology (2017)
Abstract 12497: Diminished Cavolin-1 Expression and Augmented Nitrative Stress Secondary to Prolyl-4 Hydroxylase 2 Deficiency Contribute to Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension
Authors: Zhiyu Dai, Maggie M. Zhu, You-Yang Zhao
Journal: Circulation (2016)

Background: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increased pulmonary vascular resistance and vascular remodeling. Our recent study for the first time demonstrated that loss of prolyl-4 hydroxylase 2 (PHD2) in endothelial cells and bone marrow cells in mice induces severe PAH with obliterative pulmonary vascular remodeling and plexiform-like lesions recapitulating clinical PAH. However, it is unclear whether nitrative stress is involved in the pathogenesis of PAH in this mouse model. Methods: Endothelial-specific Egln1 (encoding PHD2) disruption ( Egln1 Tie2 ), Egln1 and Hif2a double knockout ( EH2 ) mice were generated. Western blotting and immunostaining were performed to quantify nitration stress and caveolin-1 expression in WT, Egln1 Tie2 and EH2 mice. MnTMPyP (a superoxide scavenger) were administrated to Egln1 Tie2 mice. Right ventricular systolic pressure (RVSP) and RV/(LV+S) ratio, indicator of RV hypertrophy, were measured. Medial thickness and muscularization of distal pulmonary arteries were assessed by histological examination. Human lung microvascular endothelial cells (HLMECs) was cultured. Results: Nitrotyrosine was increased in Egln1 Tie2 mice and normalized in EH2 mice. MnTMPyP treatment inhibited RVSP increase and RV hypertrophy, and decreased medial thickness and muscularization of distal pulmonary arterials in Egln1 Tie2 mice. Mechanistically, endothelial Caveolin-1 expression was decreased in Egln1 Tie2 mice and normalized in EH2 mice. Consistently, PHD inhibitor DMOG decreased Caveolin-1 expression in HLMECs. Conclusion: These data show that loss of endothelial PHD2 suppresses Caveolin-1 expression in a HIF-2α dependent manner. Decrease of Caveolin-1 expression and resultant activation of nitration stress contribute to the severe vascular remodeling and PAH in Egln1 Tie2 mice. Thus, targeting nitrative stress is a novel therapeutic strategy for the treatment of PAH.
PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L)
Authors: V. Diéras, N. Harbeck, A.A. Joy, K.A. Gelmon, J. Ettl, S. Verma, D. Lu, E.R. Gauthier, P. Schnell, A. Mori, H.S. Rugo, R.S. Finn
Journal: Annals of Oncology (2017)
The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
Authors: N.S. Cora, B. Sergio, D.G. Ugo, P. Giuseppe, C. Simon, A. Wassim, A.A. Jose Angel, D. Gedske, F. Karim, G. Eliahu, H. Axel, J. Florence, M. Ray, S.M. Axel, P. Josep Maria, S. Brieuc, S. Srikala, G. Tony, J.R. Charles, I.S. Howard
Journal: Annals of Oncology (2017)
A comparison of Bronchial Washing Fluid (BWF) and histologic samples in the analysis of EGFR mutation in NSCLC patients
Authors: X. Zhang, M. Ye, C. Li, Q. Hu, M. Du, X. Wang, Z. Gong, D. Zhang, Q. Hong, J. Hu, L. Mei, Y. Hou, X. Zhang
Journal: Annals of Oncology (2017)
Polyethylene glycol embolics loaded with irinotecan for chemoembolization of refractory liver metastases from colorectal cancer
Authors: G. Fiorentini, D. Sarti, R. Carandina, M. Nardella, L. Mulazzani, A. Felicioli, D. Barnes Navarro, F. Mugnos Gomez, O. Zoras, C. Aliberti
Journal: Annals of Oncology (2017)
Polycystic liver disease: Hepatic venous outflow obstruction lesions of the noncystic parenchyma have major consequences
Authors: Louise Barbier, Maxime Ronot, Béatrice Aussilhou, François Cauchy, Claire Francoz, Valérie Vilgrain, Olivier Soubrane, Valérie Paradis, Jacques Belghiti
Journal: Hepatology (2017)

In patients with polycystic liver disease (PLD), development of cysts induces hepatic venous outflow obstruction (HVOO) and parenchymal modifications, challenging the paradigm of a normal noncystic liver parenchyma. The aims were to reappraise the pathology of the noncystic parenchyma, by focusing on HVOO lesions; and to investigate the association with outflow obstruction at imaging and perioperative course after liver resection. This is a retrospective study conducted in one tertiary center between 1993 and 2014. PLD patients (n = 125) who underwent resection (n = 90) or transplantation (n = 35) were included. HVOO parenchymal lesions were assessed for all patients and a liver congestion score was built. Imaging was analysed for 45 patients with computed tomography scan, and perioperative course was assessed in resected patients. At pathology, 92% of patients had HVOO lesions, with sinusoidal dilatation being the most common feature. HVOO was more severe in patients who underwent transplantation compared to liver resection, as assessed by the congestion score. At imaging, all patients had HVOO with at least two hepatic veins involved. Mosaic enhancement pattern of the parenchyma was associated with the severity of hepatic vein obstruction ( P = 0.045) and the compression of the inferior vena cava ( P = 0.014). In case of liver resection, intraoperative course was characterized by hemorrhage, related to HVOO at imaging. Ascites (44%) and liver failure (9%) in the postoperative period were associated with blood losses and transfusions. Conclusion : Hepatic venous outflow obstruction, including development of venous collaterality and parenchymal changes, is frequent in PLD and has major consequences on intraoperative bleeding and postoperative ascites and liver failure. Hepatic venous outflow obstruction should be taken into account to choose the most appropriate surgical treatment. (H epatology 2017).
Effects of Reminder Devices on Medication Adherence—An Assistive Technology Perspective
Authors: Jaclyn K. Schwartz, Adriana Foster, Roger O. Smith
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Author’s Reply: Comments on “Vitamin Pharmacogenomics: New Insight into Individual Differences in Diseases and Drug Responses”
Authors: Mou-Ze Liu, Hai-Yan He, Wei Zhang
Journal: Genomics Proteomics & Bioinformatics (2017)

The SNP 772G > A (rs602662) in exon 2 of the gene encoding fucosyl transferase (FUT2) has been found to be related with the alterations in plasma vitamin B 12 levels.GG carriers possessed lower levels of vitamin B 12 .However, we didn't know the mechanism behind this association.The author by referring to the related studies, has provided us a feasible explanation for the FUT2-based variations in vitamin B 12 levels.The ancestral (G) allele allows for normal translation of FUT2, resulting in ABH secretor phenotype, which is believed to be associated with Helicobacter pylori-induced gastritis or associated with decreased gastric intrinsic factor (GIF) secretion, therefore leading to reduced plasma B 12 levels.It provides sound evidence for us to believe that genetic polymorphisms may exert their effects on vitamin pharmacokinetics pathways, leading to varied plasma vitamin levels and different clinical consequences.Although there may be refuted responses on the mechanisms, we thank the author for enlightening us to reveal the pharmacogenomics involved in the mechanisms of vitamin variation.
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial
Authors: J.-B. Bachet, O. Lucidarme, C.B. Levache, E. Maillard, J.L. Raoul, T. Lecomte, C. Desauw, F. Brocard, S. Pernot, G. Breysacher, J.-P. Lagasse, F. Di Fiore, P.L. Etienne, O. Dupuis, A. Aleba, C. Lepage, J. Taieb
Journal: Annals of Oncology (2017)
Impact of breast cancer risk assessment in primary care: Modeling clinical outcomes and effectiveness
Authors: E. Meadows, J. L. Mershon, J. Johnston, R. Iskander, K. DeLong, D. Taylor, K. Kerlikowske, M. Weinstein
Journal: Journal of Clinical Oncology (2007)

1516 Background: Breast cancer risk assessment (RA) is rarely performed in the primary care setting due to uncertainty regarding the balance of harms and benefits in high risk women subsequently offered chemoprevention. We used a decision model to assess the potential clinical impact of several strategies involving use of routine RA in primary care. Methods: We developed a decision analytic model to compare routine breast cancer RA in primary care to usual care. The RA method was the Gail model, with a 5-year risk of &gt;1.67% being designated as high risk (varied in sensitivity analyses). We assumed that high risk women would be offered 5 years of tamoxifen and that acceptance (70%) and compliance (68%) rates would be incomplete. For women receiving tamoxifen, the relative risk (RR) of incident estrogen-receptor positive invasive breast cancer was 0.31 over the 5 years of treatment, diminishing over the next 5 years after cessation of treatment. RR’s for the other health effects associated with tamoxifen were: vertebral fracture (0.74), endometrial cancer (2.41), stroke (1.6), pulmonary embolism (PE, 3.01), and deep vein thrombosis (DVT, 1.60). The non-breast cancer health effects of tamoxifen were assumed to pertain only to the 5 years of active therapy. All RR’s were applied to age-dependent population-based incidence rates; data sources included published epidemiologic and clinical trial data; model duration was 40 years. Results: In agreement with recommended clinical use of tamoxifen, the results were sensitive to age and the Gail threshold above which chemoprevention was recommended ( Table ). The number of women needed to screen (NNS) to prevent 1 case of breast cancer is 7-fold higher among women aged 50 compared to 65 with a Gail risk of 1.67% (719 vs. 104). Conclusions: The number of women offered treatment, as well as the clinical outcomes and NNS, resulting from routine breast cancer risk assessment varies with the age at RA and treatment threshold selected. [Table: see text] No significant financial relationships to disclose.
PRODIGE 50 - ASPIK French: French double blind randomised study of aspirin versus placebo in resected stage III or high risk stage II colon cancer with PIK3CA mutation
Authors: P. Michel, T. André, V. Boige, T. Aparicio, E. Maillard, J. Bez, J. Blot, J-B. Bachet, L. Dahan, R. Guimbaud, S. Manfredi, D. Tougeron, J. Taieb, J. Selves, C. Lepage, F. Di Fiore
Journal: Annals of Oncology (2017)
Safety data from randomized phase II study of cisplatin (CDDP)+S-1 versus CDDP+pemetrexed (PEM) combined with thoracic radiotherapy (TRT) for locally advanced non-squamous (non-sq) non-small cell lung cancer (NSCLC): SPECTRA study
Authors: S. Niho, T. Yoshida, T. Akimoto, K. Sakamaki, T. Takahashi, T. Seto, M. Nishio, N. Yamamoto, T. Hida, H. Okamoto, T. Kurata, M. Satouchi, K. Goto, T. Yamanaka, Y. Ohe
Journal: Annals of Oncology (2017)
Treatment of advanced gastric cancer based on Lauren’s histological: Real-world data from the AGAMEMON National Cancer Registry
Authors: A. Carmona-Bayonas, P. Jiménez-Fonseca, R. Hernández, A. Custodio, J.M. Cano, A. Lacalle, I. Echavarria Diaz-Guardamino, I. MACIAS, M. Mangas Izquierdo, L. Visa, E. Buxo Orra, A. Azkarate, A. Ramchandani Vaswani, E. Martínez de Castro, A. Fernández Montes, F. Longo, R. Sánchez Bayona, M.L. Limón, A. Martín Carnicero, J. Gallego Plazas
Journal: Annals of Oncology (2017)
Ultrasound Elastography Pattern of lung squamous cell carcinoma: Preliminary report on a possible adjunctive tool for noninvasive imaging.
Authors: Marco Sperandeo, Guglielmo M. Trovato, Lucia Dimitri, Giuseppe Fabio Martines, Anna Simeone, Francesca M. Trovato, Angela Pamela Piscitelli, Daniela Catalano
Journal: Journal of Clinical Oncology (2013)

e18518 Background: Trans-Thoracic Ultrasound (TUS) guided Fine Needle Aspiration Biopsy (FNAB) provides a rapid and affordable method of diagnosing and staging lung cancer. It allows safe and easy access to sub-pleural masses. A total of 70% of pleural surface is accessible by TUS, and pulmonary processes, including masses, are visualized when they come up to pleura or are accessible via a sound window (e.g. pleural effusion or atelectasis), provided that no subcutaneous emphysema or pneumothorax is present. US Elastography is a novel approach useful to estimate the stiffness/elasticity of tissues. It is already a valuable tool for the definition of nodules (thyroid, breast, prostate cancer). The aim of our study was to assess if TUS Elastography of concurrent FNAB-proven lung cancer could be of help for a preliminary histological diagnosis. Methods: TUS with Elastography and FNAB after chest x-ray and CT-scan were performed in 57 patients (m 44, f 13; years 64,63±5,96). Tissue stiffness of the subpleural masses was scored from 1 (greatest elasticity) to 5 (no elasticity) using a convex 2-8 mHz probe and a MyLab-ElaXto Esaote-Biomedica equipment. Results: By TUS, subpleural solid masses (cm. 2-5) were detected and assessed by FNAB. Histological diagnosis were: small cell lung cancer (4/57), Adenocarcinoma (29/57), Squamous Cell Carcinoma (12/57, SCC) and poorly differentiated lung carcinoma (12/57). Patients' age and mass dimension are not significantly associated with any histotype. A significant lower elasticity of SCC (4,67±0,492) is observed vs. any of the other three histotypes of cancer (P&lt;0.005). A score of 5 at Elastography is observed in 8/12 SCC and only in 7/45 of the other histotypes (χ 2 p&lt;0.0004 vs. any of the other histotypes; OR 10.857; 95% CI 2,557-46,093). By a MLR model, age, TNM and tumor dimension were not significant predictors of the Elastography score. Conclusions: TUS Elastography seems a novel imaging adjunctive tool reasonably suitable to help in the non-invasive diagnosis of Lung Squamous Cell Carcinoma.
The athlete's hematological response to hypoxia: A meta‐analysis on the influence of altitude exposure on key biomarkers of erythropoiesis
Authors: Louisa M. Lobigs, Ken Sharpe, Laura A. Garvican‐Lewis, Christopher J. Gore, Peter Peeling, Brian Dawson, Yorck O. Schumacher
Journal: American Journal of Hematology (2017)

Altitude training is associated with changes in blood markers, which can confound results of the Athlete?s Biological Passport (ABP). This meta-analysis aims to describe the fluctuations during- and post-altitude in key ABP variables; hemoglobin concentration ([Hb]), square-root transformed reticulocyte percentage (sqrt(retic%)) and the OFF-score. Individual de-identified raw data were provided from 17 studies. Separate linear mixed effects analyses were performed for delta values from baseline for [Hb], sqrt(retic%) and OFF-score, by altitude phase (during and post). Mixed models were fitted with the hierarchical structure: study and subject within study as random effects. Delta values as response variables and altitude dose (in kilometer hours; km.hr = altitude (m) / 1000 x hours), sex, age, protocol and baseline values as fixed effects. Allowances were made for potential autocorrelation. Within two days at natural altitude [Hb] rapidly increased. Subsequent delta [Hb] values increased with altitude dose, reaching a plateau of 0.94 g/dL [95%CI (0.69, 1.20)] at ~1000 km.hr. Delta sqrt(retic%) and OFF-score were the first to identify an erythrocyte response, with respective increases and decreases observed within 100 to 200 km.hr. Post-altitude, [Hb] remained elevated for two weeks. Delta sqrt(retic%) declined below baseline, the magnitude of change was dependent on altitude dose. Baseline values were a significant covariate (p<0.05). The response to altitude is complex resulting in a wide range of individual responses, influenced primarily by altitude dose and baseline values. Improved knowledge of the plausible hematological variations during- and post-altitude provides fundamental information for both the ABP expert and sports physician.
Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape
Authors: J. Bedke, M. Welslau, M. Boegemann, M. Schostak, C. Hering-Schubert, A. Petzoldt, T. Wolf, J. Schleicher, C. Doehn, C. Grüllich, V. Grünwald, T. Steiner, R. Ehness, D. Klein, T. Medinger, P.J. Goebell
Journal: Annals of Oncology (2017)
Abstract 166: Qiliqiangxin Attenuates Doxorubicin-induced Cardiomyopathy via Regulating Autophagy
Authors: Shutong Shen, Lichan Tao, Xiaoting Wu, Junjie Xiao, Xinli Li
Journal: Circulation Research (2015)

Aims: Doxorubicin-induced cardiomyopathy, as a common complication of cancer chemotherapy, greatly limits the clinical implication of doxorubicin in the treatment of cancer. Our previous clinical trial and animal studies have shown that Qiliqiangxin, a traditional Chinese medication, was protective for adverse cardiac remodeling. This study aimed at determine the therapeutic effect of Qiliqiangxin in mouse doxorubicin-induced cardiomyopathy. Methods and results: Three groups of mice (control, n=6; doxorubicin+saline, n=7; doxorubicin+Qiliqiangxin, n=7) were followed up for 4 weeks. Echocardiography was taken at the end of 4 weeks to evaluate cardiac function. Mice from the doxorubicin+saline group showed reduced ejection fraction (EF) and fractional shortening (FS) as compared with the mice from the control group. Qiliqiangxin could partly restore the reduction of EF and FS in doxorubicin-induced cardiomyopathy mice. Genes related with autophagosome formation (becline1, ATG4, ATG7, LC3) and autophagosome-lysosome fusion (Cathepsin B, Cathepsin D, Cathepsin L) were determined by quantitative reverse transcription polymerase chain reactions (RT-PCRs) in heart samples from mice of the three groups (control, doxorubicin+saline, doxorubicin+Qiliqiangxin) at the end of 4 weeks. All these 7 genes were found to be increased in doxorubicin-induced cardiomyopathy mice, implying doxorubicin may disturb the autophagy flux of mice hearts through promoting autophagosome formation and inhibiting autophagosome-lysosome fusion. Interestingly, the expression of these 7 genes were decreased in the doxorubicin+Qiliqiangxin group, implying that Qiliqiangxin may protect the cardiac function in doxorubicin-treated mice through regulating the autophagy flux of mice hearts. Moreover, autophagy-related proteins LC3 and P62 were determined by western blotting. Qiliqiangxin reversed the increase of LC3II level and the decrease of P62 level in the doxorubicin-treated mice hearts. Conclusion: Qiliqiangxin may protect the cardiac function of doxorubicin-induced heart failure mice through regulating autophagy in the heart. Qiliqiangxin might be a novel drug for doxorubicin-induced cardiomyopathy.
External validation of modified breast graded prognostic assessment for breast cancer patients with brain metastases
Authors: G. Griguolo, W. Jacot, E. Kantelhardt, M.V. Dieci, C. Bourgier, C. Thomssen, C. Bailleux, F. Miglietta, A.L. Braccini, P.F. Conte, J-M. Ferrero, V. Guarneri, A. Darlix
Journal: Annals of Oncology (2017)